Categories: Corporate and commercial, Civil Law Notaries, Private Equity & Venture Capital, Startup Desk
GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, announced the closing of an oversubscribed USD 130m Series-B-financing. The proceeds will be used to advance the Company’s lead IgG4-targeted protein degrader through clinical data in patients, bring a second program to the clinic and further develop its differentiated pipeline of precision extracellular degraders in immunology and additional indications. VISCHER advised GlycoEra AG on all legal issues related to the transaction.
The VISCHER team includes Matthias Staehelin, Pauline Pfirter, Timothy Woodtli and Natacha Tang (all Corporate/M&A).
Author: Pauline Pfirter
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]
